NASDAQ:TCRT Alaunos Therapeutics (TCRT) Stock Price, News & Analysis → Bill Clinton Backing Biden Replacement??? (From The Freeport Society) (Ad) Free TCRT Stock Alerts $1.07 -0.01 (-0.93%) (As of 06/5/2024 ET) Add Compare Share Share Today's Range$1.04▼$1.1050-Day Range$1.04▼$1.8252-Week Range$0.66▼$7.96Volume28,545 shsAverage Volume36,419 shsMarket Capitalization$17.13 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Alaunos Therapeutics alerts: Email Address Ad The Freeport SocietyBill Clinton Backing Biden Replacement???Bill Clinton is back. And he just met in Mexico with the one person I believe could REPLACE Joe Biden by August…Click here now for my urgent election forecast. About Alaunos Therapeutics Stock (NASDAQ:TCRT)Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology. The company was founded in 2003 and is headquartered in Houston, Texas.Read More TCRT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TCRT Stock News HeadlinesMay 16, 2024 | investorplace.comTCRT Stock Earnings: Alaunos Therapeutics Reported Results for Q1 2024April 12, 2024 | seekingalpha.comRevolution Medicines: An Expensive Shot At A Massive Market OpportunityApril 8, 2024 | investorplace.comTCRT Stock Earnings: Alaunos Therapeutics Misses EPS for Q4 2023April 1, 2024 | msn.comBiora Therapeutics announces $6M registered direct offering and concurrent private placementJanuary 31, 2024 | msn.comAlaunos Therapeutics Announces 1-for-15 Reverse Stock SplitJanuary 31, 2024 | investing.comWerewolf Therapeutics Inc (HOWL)December 28, 2023 | benzinga.comAlaunos Therapeutics Stock (NASDAQ:TCRT) Dividends: History, Yield and DatesNovember 14, 2023 | benzinga.comRecap: Alaunos Therapeutics Q3 EarningsNovember 14, 2023 | investorplace.comWhy Is Alaunos Therapeutics (TCRT) Stock Up 14% Today?November 14, 2023 | finance.yahoo.comAlaunos Therapeutics Announces Third Quarter 2023 Financial Results, Phase 1 Clinical Data and Continued Exploration of Strategic AlternativesNovember 1, 2023 | morningstar.comAlaunos Therapeutics Inc TCRTAugust 15, 2023 | msn.comWhy Is Alaunos Therapeutics Sinking Today?August 14, 2023 | finance.yahoo.comAlaunos Therapeutics Announces Second Quarter 2023 Financial Results, Interim Clinical Data and Exploration of Strategic AlternativesJune 29, 2023 | finance.yahoo.comAlaunos Therapeutics Announces Presentation at the 2nd Hawaii Global Summit on Thoracic MalignanciesJune 9, 2023 | benzinga.comAlaunos Therapeutics Stock (NASDAQ:TCRT), Insider Trading ActivityMay 26, 2023 | msn.comAlaunos slips 17% on Phase 1/2 data for cancer cell therapyMay 25, 2023 | finance.yahoo.comAlaunos Therapeutics to Present Early Data from TCR-T Library Phase 1/2 Trial at 2023 American Society of Clinical Oncology Annual MeetingMay 17, 2023 | uk.news.yahoo.comOne Alaunos Therapeutics Insider Raised Stake By 117% In Previous YearMay 15, 2023 | seekingalpha.comAlaunos Therapeutics upgraded to buy at Wainwright on multiple catalystsMay 13, 2023 | finance.yahoo.comAlaunos Therapeutics, Inc. (NASDAQ:TCRT) Q1 2023 Earnings Call TranscriptMay 11, 2023 | marketwatch.com8-K: Alaunos Therapeutics, Inc.May 10, 2023 | finanznachrichten.deAlaunos Therapeutics, Inc.: Alaunos Therapeutics Reports First Quarter 2023 Financial ResultsMay 10, 2023 | msn.comAlaunos Therapeutics GAAP EPS of -$0.04 in-lineMay 10, 2023 | msn.comRecap: Alaunos Therapeutics Q1 EarningsMay 10, 2023 | finance.yahoo.comAlaunos Therapeutics Reports First Quarter 2023 Financial ResultsSee More Headlines Receive TCRT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alaunos Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/14/2023Today6/06/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:TCRT CUSIPN/A CIK1107421 Webwww.alaunos.com Phone(346) 355-4099Fax617-241-2855Employees1Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-35,140,000.00 Net MarginsN/A Pretax Margin-446,233.34% Return on Equity-229.55% Return on Assets-173.67% Debt Debt-to-Equity RatioN/A Current Ratio4.87 Quick Ratio4.87 Sales & Book Value Annual Sales$6,000.00 Price / Sales2,855.65 Cash FlowN/A Price / Cash FlowN/A Book Value$0.39 per share Price / Book2.74Miscellaneous Outstanding Shares16,013,000Free Float15,195,000Market Cap$17.13 million OptionableOptionable Beta-0.31 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. Dale Curtis Hogue Jr. (Age 54)Interim CEO & Director Ms. Melinda Lackey (Age 47)Senior VP of Legal, Administration & Secretary Comp: $625.12kMr. Michael Wong (Age 44)Vice President of Finance & Principal Accounting Officer Key CompetitorsSpruce BiosciencesNASDAQ:SPRBAeglea BioTherapeuticsNASDAQ:AGLEMediciNovaNASDAQ:MNOVLantern PharmaNASDAQ:LTRNAileron TherapeuticsNASDAQ:ALRNView All CompetitorsInsiders & InstitutionsVirtu Financial LLCBought 15,440 shares on 5/20/2024Ownership: 0.096%Magnolia Capital Advisors LLCSold 376,812 shares on 5/2/2024Ownership: 0.154%Fortis Group Advisors LLCBought 13,999 shares on 4/30/2024Ownership: 0.087%Kevin S Sr. BoyleSold 4,534 sharesTotal: $9,521.40 ($2.10/share)View All Insider TransactionsView All Institutional Transactions TCRT Stock Analysis - Frequently Asked Questions Should I buy or sell Alaunos Therapeutics stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Alaunos Therapeutics in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" TCRT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TCRT, but not buy additional shares or sell existing shares. View TCRT analyst ratings or view top-rated stocks. How have TCRT shares performed in 2024? Alaunos Therapeutics' stock was trading at $1.0605 at the beginning of the year. Since then, TCRT stock has increased by 0.9% and is now trading at $1.07. View the best growth stocks for 2024 here. When is Alaunos Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024. View our TCRT earnings forecast. How were Alaunos Therapeutics' earnings last quarter? Alaunos Therapeutics, Inc. (NASDAQ:TCRT) released its quarterly earnings data on Tuesday, November, 14th. The company reported ($0.60) EPS for the quarter, missing analysts' consensus estimates of ($0.45) by $0.15. When did Alaunos Therapeutics' stock split? Shares of Alaunos Therapeutics reverse split on the morning of Thursday, February 1st 2024. The 1-15 reverse split was announced on Thursday, February 1st 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, February 1st 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. Who are Alaunos Therapeutics' major shareholders? Alaunos Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Magnolia Capital Advisors LLC (0.15%), Virtu Financial LLC (0.10%) and Fortis Group Advisors LLC (0.09%). Insiders that own company stock include Kevin S Sr Boyle and Robert W Postma. View institutional ownership trends. How do I buy shares of Alaunos Therapeutics? Shares of TCRT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TCRT) was last updated on 6/6/2024 by MarketBeat.com Staff From Our Partners"The Biggest Drug Ever" Is ComingUBS bank predicts it will become "The Biggest Drug Ever." The Wall Street Journal believes it will be "Phar...Behind the Markets | SponsoredWas the Great Financial Crisis fun?The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, ...Brooks Enterprises | Sponsored[Webinar] Understanding Covered CallsDiscover the details of this option-selling strategy.OIC | SponsoredMissed NVDA? Buy this AI stock NOWAfter Nvidia's record-breaking earnings surge, Wall Street is now selling the stock at the fastest pace in sev...Chaikin Analytics | SponsoredBUY ALERT: Tiny tech play partners with US governmentThe Federal Reserve is rolling out a powerful new financial technology across the entire U.S. banking system. ...Stansberry Research | SponsoredBitcoin’s Biggest Year Yet2024 is set to be a historic year for Bitcoin. It’s all thanks to three major catalysts that I reveal in my...Paradigm Press | SponsoredClaim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an eff...Crypto Swap Profits | SponsoredAre You Positioned For The New Energy Goldrush?Open AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alaunos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alaunos Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.